Idenix Pharmaceuticals, Inc. · Cambridge, MA United States (NASDAQ: IDIX)
| 60 Hampshire St. | Phone: 617-995-9800 |
| Cambridge, MA | Fax: 617-995-9801 |
| 02139 | |
| United States |
Idenix Pharmaceuticals, Inc. Rankings
Company Description
Idenix Pharmaceuticals is not suffering from an identity crisis -- it is clear in its focus on identifying treatments for viral diseases. The firm develops orally administered drugs to combat chronic hepatitis C (HCV). It has one marketed drug for hepatitis B (HBV), Telbivudine, sold under the brand names Tyzeka in the US and Sebivo internationally. It markets the product with
Financials
| Company Type | Public - NASDAQ: IDIX Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 109 |
Executives
28 executives listed for Idenix Pharmaceuticals, Inc.'s Cambridge, MA location.
| President, CEO, and Director | Ronald Renaud | |
|---|---|---|
| EVP and Chief Scientific Officer | David Standring | |
| EVP Clinical Development and Chief Medical Officer | Douglas Mayers |


